Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - levothyroxine sodium, quantity: 0.2 mg - tablet, uncoated - excipient ingredients: dextrin; magnesium stearate; lactose monohydrate; maize starch - oroxine is indicated for the management of demonstrated thyroid hormone deficiency.,oroxine is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - levothyroxine sodium, quantity: 0.1 mg - tablet, uncoated - excipient ingredients: dextrin; lactose monohydrate; maize starch; magnesium stearate - oroxine is indicated for the management of demonstrated thyroid hormone deficiency.,oroxine is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - levothyroxine sodium, quantity: 0.05 mg - tablet, uncoated - excipient ingredients: dextrin; magnesium stearate; lactose monohydrate; maize starch - oroxine is indicated for the management of demonstrated thyroid hormone deficiency.,oroxine is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amiodarone hydrochloride, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; colloidal anhydrous silica; povidone; maize starch - severe cases of tachyarrhythmias (e.g wolf-parkinson-white syndrome; supraventricular, nodal and ventricular tachycardias; atrial flutter and fibrillation; ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg thyroid function, chest x-ray, ophthalmological examination, hepatic function) during the entire course of therapy and for several months after discontinuation.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amiodarone hydrochloride, quantity: 100 mg - tablet, uncoated - excipient ingredients: crospovidone; microcrystalline cellulose; purified talc; povidone; lactose monohydrate; magnesium stearate; colloidal anhydrous silica - severe cases of tachyarrhythmias (e.g. wolff-parkinson-white syndrome; supraventricular, nodal and ventricular tachycardias; atrial flutter and fibrillation; ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (e.g. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amiodarone hydrochloride, quantity: 200 mg - tablet, uncoated - excipient ingredients: povidone; lactose monohydrate; purified talc; microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica - severe cases of tachyarrhythmias (e.g. wolff-parkinson-white syndrome; supraventricular, nodal and ventricular tachycardias; atrial flutter and fibrillation; ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (e.g. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amiodarone hydrochloride, quantity: 200 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; lactose monohydrate; colloidal anhydrous silica; magnesium stearate - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachycardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - levothyroxine sodium, quantity: 0.2 mg - tablet - excipient ingredients: magnesium stearate; pregelatinised starch; microcrystalline cellulose; hyprolose; allura red ac aluminium lake - levothyroxine sodium is indicated for the management of demonstrated thyroid hormone deficiency.,levothyroxine sodium is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levothyroxine sodium, quantity: 50 microgram - tablet, uncoated - excipient ingredients: sodium starch glycollate; sodium stearylfumarate; microcrystalline cellulose; light magnesium oxide - levothox is indicated for the management of demonstrated thyroid hormone deficiency.,levothox is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levothyroxine sodium, quantity: 200 microgram - tablet, uncoated - excipient ingredients: light magnesium oxide; sodium starch glycollate; sodium stearylfumarate; microcrystalline cellulose; allura red ac aluminium lake - levothox is indicated for the management of demonstrated thyroid hormone deficiency.,levothox is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.